Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Javier Cortes, MD, PhD
Komal Jhaveri, MD, FACP
Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
Jennifer I. Lim, MD, FARVO
Carl Regillo, MD
Heads Up: It Might Be ATTRv Polyneuropathy – A Microlearning Course on Diagnosis and Treatment
John Berk, MD
Noel Dasgupta, MD, FACC
Sami Khella, MD
Marcia Waddington-Cruz, MD, PhD
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
ATTRv-PN: A Complicated Disease With a Poor Prognosis
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Jeffrey V. Matous, MD
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
Omer Abdul Hamid, MD
Nancy Kuntz, MD
Migvis Monduy, MD
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
Quality Indicators: How Do You Compare? Part 1
Douglas Rex, MD
Aasma Shaukat, MD, MPH
Patient Education: Telling Is Not Teaching and Listening Is Not Learning
David Johnson, MD
Bowel Prep Hesitancy: What's It All About?
Don't Flush Another Colonoscopy Down the Toilet
Another Inadequate Bowel Prep? It May Not Be the Patient's Fault
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
Susana Campos, MD, MPH
Hematologic Adverse Events With ADCs in Breast Cancer: Optimal Management Strategies
Nadia Harbeck, MD, PhD
ADC-Related Hematologic Adverse Events
Egbert Smit, MD
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.